<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04745494</url>
  </required_header>
  <id_info>
    <org_study_id>16/0679</org_study_id>
    <nct_id>NCT04745494</nct_id>
  </id_info>
  <brief_title>Studies of Mothers With Postnatal Depression</brief_title>
  <official_title>Studies of Mothers With Postnatal Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the effects of a single dose of oxytocin (OT) delivered via a nasal&#xD;
      spray in women with and without traits of postnatal depression (PND).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double-blind, placebo-controlled, case-controlled, randomised controlled-trial,&#xD;
      within-subjects, cross-over design will be conducted.&#xD;
&#xD;
      Participants will include mothers and their infant in the postnatal period. All participants&#xD;
      will be screened for symptoms of low mood on the Edinburgh Postnatal Depression Scale (EPDS)&#xD;
      and then assigned into 2 groups comprising probable PND cases and controls.&#xD;
&#xD;
      All participants will take part in 3 conditions at Baseline (before nasal spray&#xD;
      administration), Condition 1 (after first OT/Placebo administration) and Condition 2 (after&#xD;
      second OT/Placebo administration), and will complete the same order of tasks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 12, 2017</start_date>
  <completion_date type="Actual">January 30, 2021</completion_date>
  <primary_completion_date type="Actual">March 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Double-blind, placebo-controlled, case-controlled, randomised controlled-trial, within-subjects, cross-over design.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in maternal mood</measure>
    <time_frame>Baseline, 35-45 minutes after intervention administration</time_frame>
    <description>Change in maternal mood will be assessed using the PANAS questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in maternal mindmindedness</measure>
    <time_frame>Baseline, 35-45 minutes after intervention administration</time_frame>
    <description>Change in maternal mindmindedness will be assessed using Meins' Mindmindedness Manual</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mother-infant interactional style</measure>
    <time_frame>Baseline, 35-45 minutes after intervention administration</time_frame>
    <description>Change in mother-infant interactional style will be coded using Feldman's Coding Interactive Behaviour Manual</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in maternal OT</measure>
    <time_frame>Baseline, 35-45 minutes after intervention administration</time_frame>
    <description>Change in maternal salivary and breast milk OT will be assayed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in infant OT</measure>
    <time_frame>Baseline, 35-45 minutes after intervention administration</time_frame>
    <description>Change in infant salivary OT will be assayed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal gaze during interaction with her infant</measure>
    <time_frame>35-45 minutes after intervention administration</time_frame>
    <description>Maternal gaze will be assessed using a Tobii X2-30 eye tracker</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Postnatal Depression</condition>
  <arm_group>
    <arm_group_label>OT administration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All participants will receive a single dose of 24IU OT (40.32µg, Syntocinon) delivered via a nasal spray.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo administration</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>All participants will receive a single dose of a placebo delivered via a nasal spray.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>OT administration</intervention_name>
    <description>OT nasal administration</description>
    <arm_group_label>OT administration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo administration</intervention_name>
    <description>Placebo nasal administration</description>
    <arm_group_label>Placebo administration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All mothers will be aged ≥18 years old.&#xD;
&#xD;
          -  Mothers in the clinical group will score above the clinical cut-off point on the EPDS.&#xD;
&#xD;
          -  Mothers in the control group will score below the clinical cut-off point on the EPDS.&#xD;
&#xD;
          -  Mothers must be able to read and write English at a level sufficient to complete study&#xD;
             related assessments.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  If the mother is younger than 18 or post-menopausal&#xD;
&#xD;
          -  If the pregnancy was a result of fertility treatment&#xD;
&#xD;
          -  If the mother is pregnant&#xD;
&#xD;
          -  If the mother has history of psychotic illness&#xD;
&#xD;
          -  If the mother is at risk of self-harm&#xD;
&#xD;
          -  If the mother is involved in other active drug trials&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University College London</name>
      <address>
        <city>London</city>
        <state>UK</state>
        <zip>WC1E 7HB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 25, 2020</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2021</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oxytocin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression, Postpartum</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

